INTERIM RESULTS FROM A PHASE 1B CLINICAL TRIAL EVALUATING TOLERABILITY AND ACTIVITY OF FGFR INHIBITION IN LOCALIZED UPPER TRACT UROTHELIAL CARCINOMA (UTUC)

被引：0
|
作者：
Matin, Surena
Adibi, Mehrad
Shah, Amishi
Alhalabi, Omar
Corn, Paul
Guo, Charles
Amirtharaj, Rhenita
Lozano, Marisa
Xiao, Lianchun
Pal, Sumanta
Campbell, Matthew
机构：
来源：
JOURNAL OF UROLOGY | 2022年 / 207卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
LBA01-10
引用
收藏
页码：E1039 / E1040
页数：2
相关论文
共 50 条
  • [11] Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial
    Geva, Ravit
    Stemmer, Salomon
    Perets, Ruth
    Maurice-Dror, Corinne
    Ben-Ami, Eitan
    Raphael, Ari
    Kumar, Sanjeev
    Lorber, Ilana
    Kedem, Tal Hetzroni
    Fields, Scott Z.
    Rozencweig, Marcel
    Golan, Talia
    CANCER RESEARCH, 2023, 83 (08)
  • [12] RADIOGRAPHIC PREDICTORS OF PATHOLOGIC RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH HIGH-GRADE UPPER TRACT UROTHELIAL CARCINOMA: RESULTS OF A PHASE 2 CLINICAL TRIAL
    Wong, Nathan C.
    Sjoberg, Daniel
    Ghafoor, Soleen
    Vargas, H. Alberto
    Silva, Nicholas
    Bochner, Bernard H.
    Dalbagni, Guido
    Donat, S. Machele
    Herr, Harry W.
    Cha, Eugene
    Donahue, Timothy
    Pietzak, Eugene
    Al-Ahmadie, Hikmat
    Benfante, Nicole
    Iyer, Gopa
    Teo, Min Yuen
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    Coleman, Jonathan A.
    JOURNAL OF UROLOGY, 2020, 203 : E375 - E375
  • [13] Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial
    Sweis, Randy F.
    Gajate, Pablo
    Morales-Barrera, Rafael
    Lee, Jae-Lyun
    Necchi, Andrea
    de Braud, Filippo
    Penel, Nicolas
    Gruenwald, Viktor
    Maruzzo, Marco
    Meran, Johannes
    Ishida, Tatiane Cristine
    Bao, Weichao
    Zhou, Yinghui
    Ellinghaus, Peter
    Rosenberg, Jonathan E.
    JAMA ONCOLOGY, 2024, 10 (11) : 1565 - 1570
  • [14] Final results of a multicenter prospective phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy in patients with high-grade upper tract urothelial carcinoma.
    Yip, Wesley
    Coleman, Jonathan
    Wong, Nathan Colin
    Sjoberg, Daniel D.
    Bochner, Bernard H.
    Dalbagni, Guido
    Donat, S. Machele
    Herr, Harry W.
    Pietzak, Eugene J.
    Hakimi, A. Ari
    Kim, Kwanghee
    Al-Ahmadie, Hikmat A.
    Vargas, Hebert Alberto
    Meraney, Anoop M.
    Baccala, Angelo Angelino
    Apolo, Andrea B.
    Iyer, Gopa
    Teo, Min Yuen
    Rosenberg, Jonathan E.
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [15] Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC)
    Zucali, P.
    Santoro, A.
    Rodriguez-Lope, C.
    Simonelli, M.
    Camacho, L. H.
    Senzer, N. N.
    Bolondi, L.
    Lamar, M.
    Abbadessa, G.
    Schwartz, B. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [16] Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
    Le Tourneau, Christophe
    Hoimes, Christopher
    Zarwan, Corrine
    Wong, Deborah J.
    Bauer, Sebastian
    Claus, Rainer
    Wermke, Martin
    Hariharan, Subramanian
    von Heydebreck, Anja
    Kasturi, Vijay
    Chand, Vikram
    Gulley, James L.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [17] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study
    Necchi, A.
    Todenhoefer, T.
    Deville, J-L
    Hackl, M.
    Marszewska, M.
    Mckernan, P.
    Saulay, M.
    Engelhardt, M.
    De Santis, M.
    EUROPEAN UROLOGY, 2023, 83 : S783 - S783
  • [18] BIOMARKER RESULTS FROM ARQ 197-114: A PHASE 1B TRIAL EVALUATING THE CMET INHIBITOR ARQ 197 IN CIRRHOTIC PATIENTS (PTS) WITH HEPATOCELLULAR CARCINOMA (HCC)
    Rodriguez-Lope, C.
    Rimassa, L.
    Bolondi, L.
    Camacho, L. H.
    Senzer, N.
    Abbadessa, G.
    Waghorn, C.
    Santoro, A.
    Bruix, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 73 - 73
  • [19] Short-term Changes in Health-related Quality of Life of Patients Undergoing Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: Results from a Prospective Phase 2 Clinical Trial
    van Doeveren, Thomas
    Remmers, Sebastiaan
    van den Bergh, Roderick C. N.
    Boeve, Egbert R.
    Atema, Vera
    Cornel, Erik B.
    van der Heijden, Antoine G.
    Hendricksen, Kees
    Cauberg, Evelyne C. C.
    Jacobs, Rens A. L.
    Kroon, Bin K.
    Leliveld, Annemarie M.
    Meijer, Richard P.
    Merks, Bob
    Oddens, Jorg R.
    Roelofs, Luc
    Somford, Diederik M.
    de Vries, Peter
    Wijsman, Bart
    Windt, Willemijn A. K. M.
    Zwaan, Peter J.
    van Leeuwen, Pim J.
    Boormans, Joost L.
    Aben, Katja K. H.
    EUROPEAN UROLOGY OPEN SCIENCE, 2024, 60 : 15 - 23
  • [20] Efficacy and safety of derazantinib (DZB) in patients with metastatic urothelial carcinoma (mUC) with activating FGFR1/2/3 genetic aberrations (GA): Results from the phase 1b/2 FIDES-02 study.
    Necchi, Andrea
    Todenhoefer, Tilman
    Deville, Jean-Laurent
    Haeckl, Manuel
    Marszewska, Michalina
    McKernan, Phil
    Saulay, Mikael
    Engelhardt, Marc
    De Santis, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
12345